24034-73-9
24034-73-9
Chemical Structure
Geranylgeraniol
- CAS No.: 24034-73-9
- Formula:C20H34O
- Molecular Weight:290.48
IUPAC Name: (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol
InChIKey: OJISWRZIEWCUBN-QIRCYJPOSA-N
SMILES: C/C(C)=C\CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CO
Biological Activity: Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Geranylgeraniol | 99.54% | Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Geranylgeraniol (Standard) | 98.93% | Geranylgeraniol (Standard) is the analytical standard of Geranylgeraniol. This product is intended for research and analytical applications. Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Geranylgeraniol-d5 | Geranylgeraniol-d5 is the deuterium labeled Geranylgeraniol (HY-W011474). Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Saputra WD, et al. Geranylgeraniol Inhibits Lipopolysaccharide-Induced Inflammation in Mouse-Derived MG6 Microglial Cells via NF-κB Signaling Modulation. Int J Mol Sci. 2021 Sep 29;22(19):10543. [Content Brief]
- [2]. Marcuzzi A, et al. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int J Mol Sci. 2016 Mar 11;17(3):365. [Content Brief]
- [3]. Preece K, et al. A toxicological evaluation of geranylgeraniol. Regul Toxicol Pharmacol. 2021 Aug;124:104975. [Content Brief]
- [4]. Giriwono PE, et al. Dietary supplementation with geranylgeraniol suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats. Eur J Nutr. 2013 Apr;52(3):1191-9. [Content Brief]
